Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that FGFR2::v status confers therapeutic sensitivity to Pemigatinib in patients with Cholangiocarcinoma.
This statement is based on a regulatory approval from the Health Canada:
PEMAZYRE (pemigatinib) is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.